Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A patient-centred system that leverages the analysis of sweat via wearable sensors may better support the management of patients with substance-use disorders.
Pharmaceutical companies continue to advocate for the use of in vitro models towards the reduction of animal use in drug discovery and development while acknowledging that further advancements are needed to heighten the models’ current state of readiness.
Comparisons of neural recordings across time, across subsets of neurons and across individuals requires the alignment of low-dimensional latent representations.
Robotic fingers and arms that augment the motor abilities of non-disabled individuals are increasingly feasible yet face neurocognitive barriers and hurdles in efferent motor control.
The assessment of the performance of molecular assays would benefit from quantifying the resolution of molecular concentration — a new metric that we propose and evaluate here.
In biomedical studies, the environmental conditions used in mammalian cell culture are often underreported, and are seldom monitored or controlled. Best-practice standards are urgently needed.
The proliferation of synthetic data in artificial intelligence for medicine and healthcare raises concerns about the vulnerabilities of the software and the challenges of current policy.
Proactive efforts towards the development of new vaccines and antivirals, and the elimination of bottlenecks in vaccine development, will be essential to containing and eradicating future pandemics.
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
The European Union’s new regulatory framework for medical devices has central implications for the development of new devices, particularly by start-ups.
As an intermediary between cells and scaffolding biomaterials, the extracellular matrix secreted by the cells offers challenges and opportunities for the design and fabrication of engineered tissues.
The safety and security of medical devices driven by software, the software-development processes, and the need for data collection and privacy, all offer challenges and opportunities for device regulation and clinical care.
The development of implantable electrode arrays that broadly and seamlessly integrate with brain tissue will require innovation that responsibly considers clinically relevant neuroethical concerns.
Bringing truly personalized cancer vaccination with tumour neoantigens to the clinic will require overcoming the challenges of optimized vaccine design, manufacturing and affordability, and identification of the most suitable clinical setting.
Interventional healthcare will evolve from an artisanal craft based on the individual experiences, preferences and traditions of physicians into a discipline that relies on objective decision-making on the basis of large-scale data from heterogeneous sources.
